Liquidia raises ~$100M from stock offerings and RIFA advance for YUTREPIA development

Liquidia Corp

Public offering of 6,460,674 shares at $8.90/share for ~$57.5M gross; private placement of 1,123,595 shares at $8.90/share for $10M.
Fifth Amendment to RIFA with HCR provides additional $32.5M, bringing total RIFA to $100M; funding condition met upon stock offering close.
Modified fixed payment schedule extends RIFA termination from 2029 to 2031; $23.8M payment deferred to 2026.
Proceeds to fund YUTREPIA commercial development, pediatric/WHO Group 1/3 trials, and L606 clinical development.
BofA Securities sole bookrunner; fund affiliated with Paul Manning invested ~$3M in offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.